Lanadelumab Improves Quality of Life for Children With HAE and Caregivers

A retrospective registry analysis presented at the ACAAI 2026 meeting indicates that lanadelumab prophylaxis significantly improves the quality of life for children with hereditary angioedema. Caregivers reported reduced burden and better patient outcomes after long-term treatment with the medication.
Why it matters
This study provides clinical evidence for the efficacy of long-term prophylactic treatment in pediatric populations, potentially influencing future standard-of-care guidelines.
Lanadelumab (Takhzyro) prophylaxis was associated with improved quality of life (QoL) for children with hereditary angioedema (HAE) and their caregivers, according to a retrospective registry analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix.¹
The US Food and Drug Administration (FDA) expanded the lanadelumab label to include patients aged 2 to <12 years in February 2023, based on the open-label phase 3 SPRING study and efficacy data extrapolated from the phase 3 HELP study.²˒³ SPRING reported large gains in caregiver-reported Pediatric Quality of Life Inventory (PedsQL) scores across 52 weeks of treatment.² The new analysis, presented as a late-breaker by William R. Lumry, MD, examines how long-term prophylaxis affects QoL and caregiving burden in routine practice.¹
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in